1. South Korea Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Xcell Therapeutics, Inc.

Xcell Therapeutics, Inc.

KKRX:373110
1,028.00
KRW
-18.00
(-1.72%)
-740.96EPS
20.77BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
41.12
125.09
196.97
96.7
105.43
160.48
167.3
284.03
Basic EPS, GAAP
-2,239.07
-2,344.47
-905.42
-790.9
-870.57
-791.73
-938
-740.96
Free Cash Flow per Basic Share
-3,133.31
-1,313.96
-601.13
-817.24
-658.26
-648.47
-917.25
-710
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-684.61
57.27
1,469.39
768.3
215.86
693.28
412.74
250.17
Tangible Book Value per Share
-696.02
34.89
1,447.77
740.45
204.53
652.44
372.61
212.55
Basic Weighted Avg Shares
2
4
10
11
11
12
12
15
Sales/Revenue/Turnover
86
540
1,966
1,020
1,124
1,934
1,949
4,357
Operating Margin (%)
-5,065.96
-826.26
-290.14
-813.59
-771.29
-482.33
-556.79
-259.36
Depreciation Expense
591
682
1,019
1,513
1,598
1,653
1,704
1,639
Net Income, GAAP
-4,661
-10,124
-9,038
-8,342
-9,281
-9,543
-10,927
-11,365
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-5,444.97
-1,874.2
-459.67
-817.85
-825.74
-493.35
-560.65
-260.88
Working Capital
-1,116
998
10,167
2,029
-1,022
5,605
4,305
1,436
LT Debt
592
1,123
1,738
1,398
1,843
1,648
1,423
1,244
Total Equity
-7,244
632
16,225
8,483
2,384
9,121
7,138
4,327
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-107.24
-67.53
-170.8
-165.9
-134.41
-271.41

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,064
3,964
4,139
LT Borrowings
1,016
987
957
LT Finance Leases
407
352
287
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
17
17
Market Capitalization
28,726
24,074
20,771

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
9,637
9,756
6,598
Cash, Cash Equivalents & STI
6,906
6,322
4,228
Accounts Receivable, Net
-114
301
151
Inventories
1,327
1,683
1,064
Total Current Liabilities
5,332
5,185
5,162
Payables & Accruals
- -
- -
- -
ST Debt
4,064
3,964
4,139
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
521.41%
-21.74%
Free Cash Flow
- -
15.78%
36.7%
Net Income, GAAP
- -
2.03%
14.5%
Sales/Revenue/Turnover
- -
59.79%
0.76%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
522
478
458
477
1,934
2025
330
221
335
1,063
1,949
2026
1,022
1,937
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-204.99
-194.2
-207.48
-197.35
-791.73
2025
-193.37
-204.99
-175.28
-247
-938
2026
-169.38
-160
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
U-Ri Lee
Full Time Employees
65
Sector
Health technology
Industry
Biotechnology
Address
Dongwon Building Seoul SL South Korea 21990
IPO Date
Jul 15, 2024
Website
xcell.co.kr
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Xcell Therapeutics, Inc. (KOSDAQ: 373110) develops and manufactures serum-free, chemically defined cell culture media and related equipment for regenerative medicine and cell therapy applications. The company offers its flagship CellCor brand portfolio, including CellCor CD MSC, the world's first GMP-grade chemically defined medium for mesenchymal stem cells (MSCs); CellCor DPC for dermal papilla cells; and CellCor SFD KERA for keratinocytes; alongside the CAMPs (Customized and Applied Medium Platform) technology platform for custom media development, OEM/ODM services, and future CDMO offerings in cell culture process engineering. It operates a GMP-certified manufacturing facility in Yongin, South Korea, with an annual capacity of 100,000 liters, and maintains R&D headquarters in Seoul's Guro-gu district, serving research institutions, cell therapy developers, and biotech firms targeting MSCs, exosomes, extracellular vesicles, cosmetics, and foodtech sectors across global markets, including 16 international distributors in Europe and the US. Founded in 2015, Xcell Therapeutics focuses on ethical, animal-component-free solutions to enhance cell proliferation efficiency, yielding up to 2X culture results through a proprietary database of over 1,000 raw materials developed over a decade of research. Recent developments include the September 2024 launch of the Exodus T-2800 automated exosome isolation and purification system, an upgraded large-scale model to support high-volume processing; tripled H1 2024 revenue year-over-year driven by large domestic orders and initial sales of exosome equipment; and accelerated global market expansion with anticipated new product introductions. In August 2024, CEO Yi-il Lee received the Minister of Health and Welfare Award for contributions to the industry.